[Application in France of the 2021 European recommendations on endometrial cancer].

[1]  P. Petrič,et al.  Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists , 2022, Cancers.

[2]  H. Mackay,et al.  Tertiary lymphoid structures critical for prognosis in endometrial cancer patients , 2021, Nature Communications.

[3]  E. Larouzee,et al.  Prospective study of fertility‐sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[4]  F. Guyon,et al.  Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). , 2021, European journal of cancer.

[5]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[6]  G. Turashvili,et al.  Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging , 2020, JAMA surgery.

[7]  H. Putter,et al.  Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Bosse,et al.  Incorporation of molecular characteristics into endometrial cancer management , 2019, Histopathology.

[9]  C. Gilks,et al.  Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.

[10]  R. Reis,et al.  Sentinel Lymph Node Mapping vs Systematic Lymphadenectomy for Endometrial Cancer: Surgical Morbidity and Lymphatic Complications. , 2019, Journal of minimally invasive gynecology.

[11]  J. Persson,et al.  Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging. , 2019, European journal of cancer.

[12]  W. E. Richards,et al.  Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. , 2019, The New England journal of medicine.

[13]  G. Bogani,et al.  Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. , 2019, Gynecologic oncology.

[14]  D. Provencher,et al.  Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. , 2019, Gynecologic oncology.

[15]  T. Satoh,et al.  Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer , 2019, International Journal of Clinical Oncology.

[16]  Jae-Weon Kim,et al.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Kwon,et al.  Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. , 2019, Current oncology.

[18]  S. Tangjitgamol,et al.  Impact of Metastatic Lymph Node to Total Lymph Node Ratio on Survival of Endometrial Cancer Patients , 2019, Gynecologic and Obstetric Investigation.

[19]  A. Sayasneh,et al.  Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[20]  G. Bogani,et al.  Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer , 2018, Tumori.

[21]  H. Putter,et al.  Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy , 2018, British Journal of Cancer.

[22]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[23]  M. Candiani,et al.  Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? , 2018, Human reproduction.

[24]  T. Anggraeni,et al.  Prophylactic salpingectomy and ovarian cancer: An evidence-based analysis , 2018, South Asian Journal of Cancer.

[25]  M. Munsell,et al.  A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. , 2017, Gynecologic oncology.

[26]  B. Yun,et al.  Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer , 2017, International Journal of Gynecologic Cancer.

[27]  A. Ivanova,et al.  A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. , 2017, The Lancet. Oncology.

[28]  V. Gebski,et al.  Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial , 2017, JAMA.

[29]  S. Bendifallah,et al.  [European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer]. , 2017, Bulletin du cancer.

[30]  M. Chun,et al.  Impact of paraaortic lymphadenectomy for endometrial cancer with positive pelvic lymph nodes: A Korean Radiation Oncology Group study (KROG 13-17). , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[32]  B. Erickson,et al.  Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. , 2015, Brachytherapy.

[33]  T. Van den Bosch,et al.  Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[34]  D. Lambrechts,et al.  Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.

[35]  C. Feltmate,et al.  Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer. , 2014, Practical radiation oncology.

[36]  H. Andersson,et al.  External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma: A Prospective, Randomized Study—Quality-of-Life Analysis , 2012, International Journal of Gynecologic Cancer.

[37]  R. Barakat,et al.  Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[39]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[40]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[41]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[42]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[43]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[44]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[45]  D. Lindsell.  1206: Minimum training recommendations for the practice of medical ultrasound in Europe , 2006 .

[46]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[47]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[48]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.